233 related articles for article (PubMed ID: 15251988)
1. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation.
Le NT; Richardson DR
Blood; 2004 Nov; 104(9):2967-75. PubMed ID: 15251988
[TBL] [Abstract][Full Text] [Related]
2. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation.
Darnell G; Richardson DR
Blood; 1999 Jul; 94(2):781-92. PubMed ID: 10397746
[TBL] [Abstract][Full Text] [Related]
3. Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21(CIP1/WAF1), but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation.
Le NT; Richardson DR
Carcinogenesis; 2003 Jun; 24(6):1045-58. PubMed ID: 12807743
[TBL] [Abstract][Full Text] [Related]
4. The role of iron in cell cycle progression and the proliferation of neoplastic cells.
Le NT; Richardson DR
Biochim Biophys Acta; 2002 Oct; 1603(1):31-46. PubMed ID: 12242109
[TBL] [Abstract][Full Text] [Related]
5. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs.
Becker E; Richardson DR
J Lab Clin Med; 1999 Nov; 134(5):510-21. PubMed ID: 10560945
[TBL] [Abstract][Full Text] [Related]
6. Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking.
Xu X; Sutak R; Richardson DR
Mol Pharmacol; 2008 Mar; 73(3):833-44. PubMed ID: 18029550
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer.
Richardson DR
Curr Med Chem; 2005; 12(23):2711-29. PubMed ID: 16305467
[TBL] [Abstract][Full Text] [Related]
8. The iron chelators Dp44mT and DFO inhibit TGF-β-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1).
Chen Z; Zhang D; Yue F; Zheng M; Kovacevic Z; Richardson DR
J Biol Chem; 2012 May; 287(21):17016-17028. PubMed ID: 22453918
[TBL] [Abstract][Full Text] [Related]
9. The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1.
Liang SX; Richardson DR
Carcinogenesis; 2003 Oct; 24(10):1601-14. PubMed ID: 12869419
[TBL] [Abstract][Full Text] [Related]
10. Molecular functions of the iron-regulated metastasis suppressor, NDRG1, and its potential as a molecular target for cancer therapy.
Fang BA; Kovačević Ž; Park KC; Kalinowski DS; Jansson PJ; Lane DJ; Sahni S; Richardson DR
Biochim Biophys Acta; 2014 Jan; 1845(1):1-19. PubMed ID: 24269900
[TBL] [Abstract][Full Text] [Related]
11. Differential targeting of the cyclin-dependent kinase inhibitor, p21CIP1/WAF1, by chelators with anti-proliferative activity in a range of tumor cell-types.
Moussa RS; Kovacevic Z; Richardson DR
Oncotarget; 2015 Oct; 6(30):29694-711. PubMed ID: 26335183
[TBL] [Abstract][Full Text] [Related]
12. HIF-1-mediated activation of transferrin receptor gene transcription by iron chelation.
Bianchi L; Tacchini L; Cairo G
Nucleic Acids Res; 1999 Nov; 27(21):4223-7. PubMed ID: 10518614
[TBL] [Abstract][Full Text] [Related]
13. Iron chelator-mediated alterations in gene expression: identification of novel iron-regulated molecules that are molecular targets of hypoxia-inducible factor-1 alpha and p53.
Saletta F; Suryo Rahmanto Y; Noulsri E; Richardson DR
Mol Pharmacol; 2010 Mar; 77(3):443-58. PubMed ID: 20023006
[TBL] [Abstract][Full Text] [Related]
14. Targeting the metastasis suppressor, NDRG1, using novel iron chelators: regulation of stress fiber-mediated tumor cell migration via modulation of the ROCK1/pMLC2 signaling pathway.
Sun J; Zhang D; Zheng Y; Zhao Q; Zheng M; Kovacevic Z; Richardson DR
Mol Pharmacol; 2013 Feb; 83(2):454-69. PubMed ID: 23188716
[TBL] [Abstract][Full Text] [Related]
15. Cellular iron depletion and the mechanisms involved in the iron-dependent regulation of the growth arrest and DNA damage family of genes.
Saletta F; Rahmanto YS; Siafakas AR; Richardson DR
J Biol Chem; 2011 Oct; 286(41):35396-35406. PubMed ID: 21852233
[TBL] [Abstract][Full Text] [Related]
16. A novel iron chelator that does not induce HIF-1 activity.
Creighton-Gutteridge M; Tyrrell RM
Free Radic Biol Med; 2002 Aug; 33(3):356-63. PubMed ID: 12126757
[TBL] [Abstract][Full Text] [Related]
17. The metastasis suppressor, N-myc downstream-regulated gene 1 (NDRG1), inhibits stress-induced autophagy in cancer cells.
Sahni S; Bae DH; Lane DJ; Kovacevic Z; Kalinowski DS; Jansson PJ; Richardson DR
J Biol Chem; 2014 Apr; 289(14):9692-709. PubMed ID: 24532803
[TBL] [Abstract][Full Text] [Related]
18. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Chaston TB; Lovejoy DB; Watts RN; Richardson DR
Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
[TBL] [Abstract][Full Text] [Related]
19. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression.
Gao J; Richardson DR
Blood; 2001 Aug; 98(3):842-50. PubMed ID: 11468187
[TBL] [Abstract][Full Text] [Related]
20. A mycobacterial iron chelator, desferri-exochelin, induces hypoxia-inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines.
Chong TW; Horwitz LD; Moore JW; Sowter HM; Harris AL
Cancer Res; 2002 Dec; 62(23):6924-7. PubMed ID: 12460908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
